Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia

RTTNews | 950天前
Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia

(RTTNews) - Pharmaceutical company Inhibikase Therapeutics, Inc. (IKT) announced Friday that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter.

IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec).

IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in stable-phase CML.

In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in non-human primates, reducing burdensome gastrointestinal side effects that occur following oral administration.

Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018.

IkT-001Pro will be evaluated in a single ascending dose bioequivalence study and will enroll approximately 64 male and female healthy volunteers aged 25 to 55 who will receive IkT-001Pro at one of four doses.

For More Such Health News, visit rttnews.com

read more
Sensex, Nifty Rally As IT, Bank Stocks Rebound

Sensex, Nifty Rally As IT, Bank Stocks Rebound

Indian shares bounced back on Wednesday, after having suffered heavy losses in the previous session amid heightened uncertainty over U.S. President Donald Trump's tariff announcements expected later in the day.
RTTNews | 4小时25分钟前
CAC 40 Modestly Lower In Cautious Trade

CAC 40 Modestly Lower In Cautious Trade

French stocks are down Wednesday morning on a fresh round of selling by investors ahead of U.S. President Donald Trump's "reciprocal tariff" announcement later in the day.
RTTNews | 4小时45分钟前